Medical Devices Mexico

Mexico Companion Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Mexico Companion Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Mexico · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $108.5 Mn Placeholder estimate
Estimate 2025 $120.6 Mn 1.4% of the global market
Projected 2034 $311.0 Mn 157.9% Adds $190.4 Mn over 9 forecast years
CAGR 2025–2034 11.1% Faster than 65% of 173 Medical Devices markets here
Key players 5
  • Mexico is 1.4% of the global market.
  • In Latin America, the largest is Brazil at $187.5 Mn.
  • Fastest growing: Brazil at 11.8% a year.
  • Mexico ranks 3rd of 3 by size in Latin America.

Market size projection

Mexico

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$190.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Companion Diagnostics Market market size by year, Mexico
YearMarket sizeChange that yearSince 2025
2024 (estimate) $108.5 Mn — —
2025 (base) $120.6 Mn +$12.0 Mn —
2026 (forecast) $134.0 Mn +$13.4 Mn +11.1%
2027 (forecast) $148.9 Mn +$14.9 Mn +23.4%
2028 (forecast) $165.4 Mn +$16.5 Mn +37.1%
2029 (forecast) $183.7 Mn +$18.4 Mn +52.4%
2030 (forecast) $204.1 Mn +$20.4 Mn +69.3%
2031 (forecast) $226.8 Mn +$22.7 Mn +88.1%
2032 (forecast) $252.0 Mn +$25.2 Mn +108.9%
2033 (forecast) $279.9 Mn +$28.0 Mn +132.1%
2034 (forecast) $311.0 Mn +$31.1 Mn +157.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Mexico Companion Diagnostics Market Analysis at a glance
Market size, 2025$120.6 Mn placeholder estimate
Forecast, 2034$311.0 Mn placeholder estimate
Growth (CAGR), 2025–203411.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, indication and end user (see all)
Key playersRoche Diagnostics, Agilent Technologies, Qiagen N.V., Thermo Fisher Scientific Inc., Illumina, Inc. (see all)
Regulator in MexicoCOFEPRISSource: COFEPRIS. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Mexico Companion Diagnostics Market Analysis Executive Summary

Companion diagnostics are tests that show whether a patient is likely to benefit from a specific medicine, often a cancer drug.

Key segments of the companion Diagnostics market include technology (Next-Generation Sequencing, PCR and Immunohistochemistry) and indication (Lung Cancer, Breast Cancer and Colorectal Cancer).

Bar chart: Mexico Companion Diagnostics market size, 2024–2034, placeholder estimates. $108.5 Mn in 2024, $120.6 Mn in 2025 and $311.0 Mn in 2034, 11.1% CAGR.
Mexico Companion Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Mexico Companion Diagnostics Market Dynamics

Market Growth Drivers

Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the companion Diagnostics market.

Opportunity

Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the companion Diagnostics market room to grow, especially in emerging markets.

Market Restraints

Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the companion Diagnostics market.

Competitive Landscape for Companion Diagnostics Market in Mexico

The companion Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Companion Diagnostics Market in Mexico

Companion Diagnostics in Mexico: rules and payment

Medical devices need a sanitary registration from COFEPRIS before sale.⁠[1] Public care comes through IMSS for formal workers, ISSSTE for public employees, and IMSS-Bienestar for people without social security.⁠[2]

[1] COFEPRIS. Checked 14 Nov 2026.

[2] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how companion Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Mexico.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Companion Diagnostics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Companion Diagnostics in context

Mexico compared

  • Health spending per person: 761 US$ per person (2023). World: 1,317 US$ per person (2023). 2nd highest of the 4 countries we cover in Latin America.[1]
  • Doctors: 2.59 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 4 countries we cover in Latin America.[2]
  • People aged 65 and over: 8.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 4 countries we cover in Latin America.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Companion Diagnostics market in Mexico?
Placeholder estimate: about $120.6 Mn in 2025, rising to about $311.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Companion Diagnostics market in Mexico growing?
Placeholder estimate: about 11.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Companion Diagnostics market report cover?
The report splits the market by technology (Next-Generation Sequencing, PCR, Immunohistochemistry, In Situ Hybridization), indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancers) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Companion Diagnostics market?
Key players include Roche Diagnostics, Agilent Technologies, Qiagen N.V., Thermo Fisher Scientific Inc. and Illumina, Inc..
What is driving the Companion Diagnostics market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the companion Diagnostics market.
Who regulates Companion Diagnostics in Mexico?
Medical devices need a sanitary registration from COFEPRIS before sale. Source: COFEPRIS. Checked 14 Nov 2026.
How is healthcare paid for in Mexico?
Public care comes through IMSS for formal workers, ISSSTE for public employees, and IMSS-Bienestar for people without social security. Source: Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.
How much research is published on Companion Diagnostics?
PubMed lists 376 papers on Companion Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Mexico

See all

Related on diagnostics and lab testing and oncology

See the topic